Page last updated: 2024-08-17

quinoxalines and xk 469

quinoxalines has been researched along with xk 469 in 39 studies

Research

Studies (39)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (5.13)	18.2507
2000's	34 (87.18)	29.6817
2010's	3 (7.69)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Behrens, CH; Corbett, TH; Czarnecki, J; Demchick, L; Gross, JL; Harrison, BA; Heilbrun, L; Horwitz, JP; Kushner, J; LoRusso, P; McRipley, RJ; Meyer, J; Polin, L; Pugh, S; Simpson, C; Trainor, G; White, K	1
Chan, KK; Chohan, L; Gao, H; Huang, KC; Snapka, RM; Yamasaki, EF	1
Cheung, AP; Liu, P; Nguyen, N; Struble, E	1
Cheung, AP; He, J; Liu, P; Struble, E; Wang, E	1
Brill, D; Chan, KK; Ganapathi, R; Gao, H; Grabowski, DR; Li, GC; Li, L; Snapka, RM	1
Corbett, TH; Edelstein, M; Hazeldine, ST; Horwitz, JP; Kushner, J; Palomino, E; Paluch, J; Polin, L; White, K	1
Horwitz, JP; Kessel, D	1
Ding, Z; Lawrence, TS; Li, J; LoRusso, PM; Parchment, RE; Sun, Y; Wu, GS; Zhou, JY	1
Chen, BD; Lin, H; Liu, XY; Nakeff, A; Subramanian, B; Valeriote, F	1
Nakeff, A; Pisano, M; Sahay, N; Subramanian, B	1
Chan, KK; Chiu, MH; Covey, JM; Jiang, C; Zheng, H	1
Chen, BD; Lin, H; Nakeff, A; Subramanian, B	1
Chan, KK; Covey, JM; Tosca, PJ; Turner, N; Zheng, H	1
Corbett, TH; Edelstein, MK; Fontana, J; Hazeldine, S; Horwitz, JP; Kushner, J; LoRusso, P; Paluch, J; Polin, L; Pugh, S; Simpson, C; White, K	1
Corbett, T; Hazeldine, ST; Horwitz, JP; Jasti, BR; LoRusso, P; Parchment, RE; Polin, L; Poondru, S; Purohit, V	1
Baker, VV; Ding, Z; Wei, WZ; Wu, GS; Zhou, JY	1
Bouregeois, NM; Corbett, TH; Crantz, B; Hazeldine, ST; Horwitz, JP; Kushner, J; Palomino, E; Polin, L; White, K	1
Al-Katib, AM; Dandashi, MH; Mensah-Osman, EJ; Mohammad, RM	1
Al-Katib, AM; Mensah-Osman, EJ; Mohammad, RM; Osman, NI; Wu, HY	1
Chan, KK; Gao, H; Shen, LL; Snapka, RM; Yamasaki, EF	1
Al-Katib, A; Dandashi, M; Mensah-Osman, E; Mohammad, R	1
Al-Katib, AM; Mensah-Osman, EJ; Mohammad, RM	1
Ding, ZH; Du, H; Ling, ZH; Ma, SD; Yuan, CQ; Zheng, L	1
Boinpally, RR; LoRusso, PM; Parchment, RE; Zhou, SL	1
Anderson, LW; Boinpally, RR; Collins, JM; Ivy, SP; Katki, AG; Klecker, RW; LoRusso, PM; Parchment, RE	1
Corbett, TH; Hazeldine, ST; Horwitz, JP; Kushner, J; Polin, L; White, K	2
He, Y; Tabibi, SE; Yalkowsky, SH	1
Alousi, AM; Boinpally, R; DeLuca, P; Gadgeel, S; Heilbrun, LK; LoRusso, PM; Parchment, R; Wiegand, R; Wozniak, AJ	1
Hazeldine, ST; Horwitz, JP; Kessel, D; Polin, L; Reiners, JJ	1
Dorr, RT; Landowski, TH; Pourpak, A	1
Artz, A; Bivins, C; Borthakur, G; Cortes, J; Faderl, S; Giles, FJ; Godley, L; Larson, RA; Odenike, O; Ratain, MJ; Ravandi, F; Rich, E; Stock, W; Undevia, SD; Verstovsek, S; Wierda, W; Zhang, Y	1
Desai, AA; House, L; Innocenti, F; Karrison, T; Kindler, HL; Ramirez, J; Ratain, MJ; Singh, DA; Skoog, LA; Undevia, SD	1
Joiakim, A; Kleinman, M; Mathieu, PA; Reiners, JJ	1
Ding, ZH; Ling, ZH	1
Innocenti, F; Kim, TW; Ratain, MJ; Undevia, SD; Yong, WP	1
Chlenski, A; Cohn, SL; Geary, D; Guerrero, LJ; Kakodkar, NC; Kletzel, M; Peddinti, R; Salwen, HR; Tian, Y; Undevia, SD; Yang, Q	1
Gamazon, ER; Innocenti, F; Kim, TW; Liu, W; Mirkov, S; Mulkey, F; Myers, JL; Owzar, K; Ramírez, J; Ratain, MJ; Stock, W; Undevia, S; Watson, D	1
Han, XM; Hu, W; Li, C; Li, X; Li, ZY; Shen, YM; Wu, JF; Xia, QH; Yang, L	1

Trials

4 trial(s) available for quinoxalines and xk 469

Article	Year
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions. Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:4 Topics: Half-Life; Humans; Microsomes, Liver; Quinoxalines; Stereoisomerism; Structure-Activity Relationship	2005
A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor. Investigational new drugs, 2007, Volume: 25, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Injections, Intravenous; Male; Middle Aged; Neutropenia; Protein Binding; Quinoxalines; Topoisomerase II Inhibitors; Treatment Outcome	2007
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Investigational new drugs, 2008, Volume: 26, Issue:4 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Infusions, Intravenous; Leukemia; Male; Maximum Tolerated Dose; Middle Aged; Quinoxalines; Remission Induction; Stereoisomerism; Treatment Outcome	2008
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Quinoxalines; Treatment Outcome	2008

Other Studies

35 other study(ies) available for quinoxalines and xk 469

Article	Year
Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate. Investigational new drugs, 1998, Volume: 16, Issue:2 Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Female; Male; Mice; Molecular Structure; Quinoxalines	1998
XK469, a selective topoisomerase IIbeta poison. Proceedings of the National Academy of Sciences of the United States of America, 1999, Oct-12, Volume: 96, Issue:21 Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line; Centrifugation, Density Gradient; Chlorocebus aethiops; Cross-Linking Reagents; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Design; Fibroblasts; Humans; Isoenzymes; Quinoxalines; Substrate Specificity	1999
Stability-indicating high-performance liquid chromatographic assay and analysis of decomposition products of 2-[4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy]propanoic acid. Journal of chromatography. A, 2000, Feb-18, Volume: 870, Issue:1-2 Topics: Chromatography, High Pressure Liquid; Mass Spectrometry; Quinoxalines; Reproducibility of Results; Spectrophotometry, Ultraviolet	2000
Enantiomeric separation of an aryloxyphenoxypropanoic acid by CE and LC. Journal of pharmaceutical and biomedical analysis, 2000, Volume: 22, Issue:3 Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Electrophoresis, Capillary; Quinoxalines; Reproducibility of Results; Stereoisomerism	2000
Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I. Biochemical and biophysical research communications, 2001, Feb-02, Volume: 280, Issue:4 Topics: Animals; Antineoplastic Agents; Cross-Linking Reagents; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Mice; Mice, Knockout; Quinoxalines; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured	2001
Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469). Journal of medicinal chemistry, 2001, May-24, Volume: 44, Issue:11 Topics: Animals; Antineoplastic Agents; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Quinoxalines; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured	2001
Pro-apoptotic interactions between XK469 and the peripheral benzodiazepine receptor. Cancer letters, 2001, Jul-26, Volume: 168, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Binding, Competitive; Cell Nucleus; GABA-A Receptor Agonists; Intracellular Membranes; Isoquinolines; Leukemia L1210; Membrane Potentials; Mice; Mitochondria; Quinoxalines; Receptors, GABA-A; Staurosporine; Stereoisomerism	2001
The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:11 Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dose-Response Relationship, Drug; G2 Phase; Gene Expression Regulation, Neoplastic; Humans; Mitosis; Mutation; Neoplasms; Quinoxalines; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2001
Mitotic arrest induced by XK469, a novel antitumor agent, is correlated with the inhibition of cyclin B1 ubiquitination. International journal of cancer, 2002, Jan-01, Volume: 97, Issue:1 Topics: Amsacrine; Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cell Division; Colonic Neoplasms; Cyclin B; Cyclin B1; Flow Cytometry; Humans; Immunoblotting; Mitosis; Peptide Hydrolases; Quinoxalines; Spindle Apparatus; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Ubiquitin	2002
Painting with a molecular brush: genomic/proteomic interfacing to define the drug action profile of novel solid-tumor selective anticancer agents. Cytometry, 2002, Jan-01, Volume: 47, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Gene Expression Profiling; Humans; MAP Kinase Signaling System; Multigene Family; Neoplasm Proteins; Proteome; Quinoxalines	2002
Chiral pharmacokinetics and inversion of enantiomers of a new quinoxaline topoisomerase IIbeta poison in the rat. Drug metabolism and disposition: the biological fate of chemicals, 2002, Volume: 30, Issue:3 Topics: Animals; Antineoplastic Agents; Bile; Blood Proteins; Chromatography, High Pressure Liquid; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Feces; Injections, Intravenous; Male; Protein Binding; Quinoxalines; Rats; Rats, Inbred F344; Stereoisomerism; Topoisomerase II Inhibitors	2002
XK469, a novel antitumor agent, inhibits signaling by the MEK/MAPK signaling pathway. Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Cell Survival; Cyclin B; Cyclin B1; Enzyme Inhibitors; G2 Phase; Humans; MAP Kinase Kinase Kinase 1; Mitogen-Activated Protein Kinases; Mitosis; Phosphorylation; Protein Serine-Threonine Kinases; Quinoxalines; Tumor Suppressor Protein p53	2002
Chiral high-performance liquid chromatographic analysis of the enantiomers of XK469, a new antitumor agent, in plasma and urine. Journal of pharmaceutical and biomedical analysis, 2002, Apr-15, Volume: 28, Issue:2 Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Indicators and Reagents; Quinoxalines; Rats; Rats, Inbred F344; Reproducibility of Results; Spectrophotometry, Ultraviolet; Stereoisomerism	2002
Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice. Investigational new drugs, 2002, Volume: 20, Issue:1 Topics: Administration, Oral; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Infusions, Intravenous; Injections, Intravenous; Maximum Tolerated Dose; Mice; Quinoxalines; Xenograft Model Antitumor Assays	2002
Lack of in vitro-in vivo correlation of a novel investigational anticancer agent, SH 30. Investigational new drugs, 2002, Volume: 20, Issue:1 Topics: Administration, Oral; Animals; Antineoplastic Agents; Caco-2 Cells; Female; Humans; Mice; Mice, Inbred C57BL; Models, Biological; Neoplasm Transplantation; Neoplasms, Experimental; Permeability; Quinoxalines; Tumor Cells, Cultured	2002
Induction of apoptosis by the new anticancer drug XK469 in human ovarian cancer cell lines. Oncogene, 2002, Jul-04, Volume: 21, Issue:29 Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase 9; Caspases; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Mitochondria; Ovarian Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinoxalines; Tumor Cells, Cultured	2002
II. Synthesis and biological evaluation of some bioisosteres and congeners of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469). Journal of medicinal chemistry, 2002, Jul-04, Volume: 45, Issue:14 Topics: Animals; Antineoplastic Agents; Benzoxazoles; Drug Screening Assays, Antitumor; Mice; Neoplasm Transplantation; Propionates; Pyrazines; Pyridines; Quinazolines; Quinolines; Quinoxalines; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Triazines; Tumor Cells, Cultured	2002
2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model. Molecular cancer therapeutics, 2002, Volume: 1, Issue:14 Topics: Animals; Blotting, Western; Cell Division; Disease Models, Animal; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Poly(ADP-ribose) Polymerases; Quinoxalines; Time Factors; Topoisomerase II Inhibitors; Waldenstrom Macroglobulinemia	2002
2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity. Molecular cancer therapeutics, 2002, Volume: 1, Issue:14 Topics: Antigens, Neoplasm; Blotting, Western; Culture Media, Serum-Free; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Microscopy, Confocal; Microscopy, Fluorescence; Neoplasm Transplantation; Protein Isoforms; Quinoxalines; Time Factors; Tumor Cells, Cultured; Up-Regulation; Waldenstrom Macroglobulinemia	2002
DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS. Molecular pharmacology, 2003, Volume: 63, Issue:6 Topics: Antineoplastic Agents; Base Sequence; DNA; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Humans; Molecular Sequence Data; Quinoxalines; Sulfanilamides; Teniposide	2003
XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways. International journal of oncology, 2003, Volume: 23, Issue:6 Topics: Apoptosis; Blotting, Western; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclosporine; Cytochromes c; Cytosol; Densitometry; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electron Transport Complex IV; Enzyme Activation; Enzyme Inhibitors; Fas Ligand Protein; Fluorometry; Humans; Ligands; Membrane Glycoproteins; Mitochondria; Models, Biological; Poly(ADP-ribose) Polymerases; Quinoxalines; Signal Transduction; Time Factors; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53; Up-Regulation; Waldenstrom Macroglobulinemia	2003
Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Nov-15, Volume: 9, Issue:15 Topics: Animals; Cell Division; Etoposide; Humans; Mice; Mice, SCID; Quinoxalines; Transplantation, Heterologous; Waldenstrom Macroglobulinemia	2003
[Effect of XK469 and adriamycin on the growth of H460 cells in vitro and its mechanism]. Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 2004, Volume: 24, Issue:7 Topics: Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle; Cell Cycle Proteins; Cell Division; Doxorubicin; Humans; Lung Neoplasms; Quinoxalines	2004
Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration. Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:4 Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Half-Life; Injections, Intravenous; Male; Quinoxalines; Rats; Rats, Sprague-Dawley	2005
Synthetic modification of the 2-oxypropionic acid moiety in 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid (XK469), and consequent antitumor effects. Part 4. Bioorganic & medicinal chemistry, 2005, Jun-02, Volume: 13, Issue:12 Topics: Animals; Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; Fluorine; Humans; Methylation; Mice; Propionates; Quinoxalines; Structure-Activity Relationship; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2005
Solubilization of two structurally related anticancer drugs: XK-469 and PPA. Journal of pharmaceutical sciences, 2006, Volume: 95, Issue:1 Topics: 2-Hydroxypropyl-beta-cyclodextrin; Antineoplastic Agents; beta-Cyclodextrins; Chromatography, High Pressure Liquid; Ethanol; Hydrogen-Ion Concentration; Micelles; Polysorbates; Propionates; Propylene Glycol; Quinoxalines; Solubility; Solvents; Surface-Active Agents	2006
Synthesis and biological evaluation of conformationally constrained analogs of the antitumor agents XK469 and SH80. Part 5. Bioorganic & medicinal chemistry, 2006, Apr-01, Volume: 14, Issue:7 Topics: Animals; Antineoplastic Agents; Benzofurans; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Mice; Models, Molecular; Molecular Structure; Propionates; Quinolines; Quinoxalines; Structure-Activity Relationship	2006
The role of autophagy in the death of L1210 leukemia cells initiated by the new antitumor agents, XK469 and SH80. Molecular cancer therapeutics, 2007, Volume: 6, Issue:1 Topics: Androstadienes; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 7; Caspase 3; Cell Cycle; Cell Size; Cell Survival; Cytoplasmic Vesicles; Enzyme Activation; Gene Silencing; Kinetics; Leukemia; Mice; Microtubule-Associated Proteins; Peptide Hydrolases; Propionates; Quinoxalines; Tumor Stem Cell Assay; Vacuoles; Wortmannin	2007
Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. The Journal of pharmacology and experimental therapeutics, 2007, Volume: 321, Issue:3 Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Catenated; DNA, Kinetoplast; Docetaxel; Humans; Isoquinolines; Male; Melphalan; Mice; Mice, SCID; Mitoxantrone; Naphthalimides; Prostatic Neoplasms; Protein Binding; Quinoxalines; RNA Interference; Taxoids; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays	2007
The chemotherapeutic agents XK469 (2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid) and SH80 (2-{4-[(7-bromo-2-quinolinyl)oxy]phenoxy}propionic acid) inhibit cytokinesis and promote polyploidy and induce senescence. The Journal of pharmacology and experimental therapeutics, 2009, Volume: 328, Issue:3 Topics: Animals; Autophagy; Cell Division; Cell Line; Cells, Cultured; Cellular Senescence; Cytokinesis; Flow Cytometry; Mice; Peptide Hydrolases; Polyploidy; Propionates; Quinoxalines	2009
[Mechanisms of G2/M cycle arrest induced by topo IIalpha and II beta inhibitors in H460 cells]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2008, Volume: 28, Issue:12 Topics: Antigens, Neoplasm; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cell Line, Tumor; DNA Topoisomerases, Type II; DNA-Binding Proteins; G2 Phase; Humans; Lung Neoplasms; Quinoxalines; Topoisomerase II Inhibitors	2008
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9. European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:11 Topics: Anticoagulants; Aryl Hydrocarbon Hydroxylases; Binding, Competitive; Cells, Cultured; Cytochrome P-450 CYP2C9; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; International Normalized Ratio; Microsomes, Liver; Quinoxalines; Regression Analysis; Topoisomerase II Inhibitors; Warfarin	2009
The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth. Pediatric blood & cancer, 2011, Volume: 56, Issue:1 Topics: Adolescent; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Fatal Outcome; Humans; Neoplasm Metastasis; Neuroblastoma; Quinoxalines; Treatment Outcome; Xenograft Model Antitumor Assays	2011
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenetics and genomics, 2014, Volume: 24, Issue:2 Topics: Aldehyde Oxidase; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Cohort Studies; Genetic Variation; Genotype; Humans; Liver; Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Quantitative Trait Loci; Quinoxalines	2014
Design, synthesis, biological evaluation and molecular docking study on peptidomimetic analogues of XK469. European journal of medicinal chemistry, 2016, Nov-29, Volume: 124 Topics: Animals; Antineoplastic Agents; Cell Proliferation; Chemistry Techniques, Synthetic; DNA; DNA Topoisomerases, Type II; Drug Design; Humans; Mice; Molecular Docking Simulation; Neoplasm Metastasis; Peptidomimetics; Protein Conformation; Quinoxalines; Structure-Activity Relationship; Xenograft Model Antitumor Assays	2016